
Histologic variants (HV) of urothelial carcinoma (UC-V) and non-urothelial carcinomas (NUC) of the bladder and urinary tract are aggressive malignancies with poor prognosis and limited response to platinum-based chemotherapy. Despite their biological particularities and distinct immune microenvironments,...

Enfortumab vedotin plus pembrolizumab (EVP) is the standard first-line treatment for metastatic or locally advanced urothelial carcinoma (m/laUC). Real-world patients frequently present with unfavorable clinical characteristics, raising uncertainty about whether outcomes mirror those of the pivotal EV-302/KEYNOTE-A39...

The advent of the Intuitive da Vinci single-port (SP) robotic system represents a pivotal evolution in minimally invasive urologic surgery, offering enhanced dexterity, improved surgical ergonomics, and reduced patient morbidity. This review is designed to provide a comprehensive evaluation of current...

Precise perioperative risk stratification for upper tract urothelial carcinoma (UTUC) is essential. We developed a multimodal prognostic model integrating perioperative clinical data, radiomics, and deep learning (DL) features from baseline CT urography to improve survival prediction and guide adjuvant...

Urinary tract infections (UTIs) are among the most common bacterial infections in hospitalized patients, frequently caused by Gram-negative bacteria such as Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Pseudomonas aeruginosa. The increasing prevalence...